Oxford’s Vaccine Results Still Puzzle, AZ Expects Not To File With FDA
But UK, EU and India Decisions Anticipated
Executive Summary
Partners hope non-US regulators will authorize early and then await later readouts to clarify vaccine's profile, but FDA is expected to hold out for US trial data.
You may also be interested in...
How COVID-19 Defined 2020 For Biopharma
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Coronavirus Notebook: Oxford/AZ Vaccine Nears UK Approval; Argentina OKs Russia's Sputnik V
The latest round-up from the Pink Sheet of developments relating to COVID-19.
Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback
While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.